Open AccessChemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
Author(s) -
Luigi Della Gravara,
Ciro Battiloro,
Rosa Cantile,
Antonietta Letizia,
Fabiana Vitiello,
Vincenzo Montesarchio,
Danilo Rocco
Publication year - 2020
Publication title -
lung cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1974
pISSN - 1758-1966
DOI - 10.2217/lmt-2019-0018
Subject(s) - medicine , chemotherapy , atezolizumab , oncology , immune checkpoint , immunotherapy , nivolumab , cancer